← Back to Search

Antidote

Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease

Phase 4
Waitlist Available
Led By Deepak Malhotra, MD, PhD
Research Sponsored by National Institute on Aging (NIA)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved
Drug Has Already Been Approved
Pivotal Trial

Summary

The purpose of this study is to examine the effects of the digibind drug on hemodialysis patients with high blood pressure. Digibind is used to treat toxicity from digoxin and digoxin-like molecules which may contribute to high blood pressure.

Eligible Conditions
  • High Blood Pressure
  • Hemodialysis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: MediumExperimental Treatment1 Intervention
0.4mg/kg
Group II: LowExperimental Treatment1 Intervention
0.1mg/kg
Group III: HighExperimental Treatment1 Intervention
1.6 mg/kg
Group IV: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

National Institute on Aging (NIA)Lead Sponsor
1,805 Previous Clinical Trials
28,194,827 Total Patients Enrolled
University of Toledo Health Science CampusOTHER
41 Previous Clinical Trials
16,374 Total Patients Enrolled
Deepak Malhotra, MD, PhDPrincipal InvestigatorUniversity of Toledo
~2 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top